|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the 3rd Department of Medicine, Technical
University of Munich, Munich, Germany; and the Laboratory of Molecular
Biology, Division of Basic Sciences, National Cancer Institute,
National Institutes of Health, Bethesda, MD.
A recombinant anti-CD25 immunotoxin, LMB-2, has shown clinical
efficacy in hairy cell leukemia and T-cell neoplasms. Its activity in
B-cell chronic lymphocytic leukemia (B-CLL) is inferior but might be
improved if B-CLL cells expressed higher numbers of CD25 binding sites.
It was recently reported that DSP30, a phosphorothioate CpG-oligodeoxynucleotide (CpG-ODN) induces immunogenicity of B-CLL cells by up-regulation of CD25 and other antigens. The present study
investigated the antitumor activity of LMB-2 in the presence of DSP30.
To this end, B-CLL cells from peripheral blood of patients were
isolated immunomagnetically to more than 98% purity. Incubation with
DSP30 for 48 hours augmented CD25 expression in 14 of 15 B-CLL
samples, as assessed by flow cytometry. DSP30 increased LMB-2
cytotoxicity dose dependently whereas a control ODN with no CpG motif
did not. LMB-2 displayed no antitumor cell activity in the absence of
CpG-ODN as determined colorimetrically with an
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. In contrast, B-CLL growth was inhibited in 12 of 13 samples with 50% inhibition concentrations
(IC50) in the range of LMB-2 plasma levels achieved in
clinical studies. Two samples were not evaluable because of spontaneous
B-CLL cell death in the presence of DSP30. Control experiments with an
immunotoxin that does not recognize hematopoietic cells, and an
anti-CD22 immunotoxin, confirmed that sensitization to LMB-2 was
specifically due to up-regulation of CD25. LMB-2 was much less toxic to
normal B and T lymphocytes compared with B-CLL cells. In summary,
immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a
recombinant immunotoxin by modulation of its target. This new treatment
strategy deserves further attention.
(Blood. 2002;99:1320-1326) B-cell chronic lymphocytic leukemia (B-CLL) is the
most common type of leukemia in the Western hemisphere, accounting for 25% of all leukemias.1 Of CLL cases in the United States,
95% are of B-cell origin.1 This disease is characterized
by progressive accumulation of B cells with very low proliferative
capacity but prolonged cell survival.2 It has, therefore,
been suggested that mechanisms of physiologic cell death are impaired
in B-CLL cells.3
Patients whose normal hematopoiesis is compromised by leukemic
infiltration of bone marrow or by disease-related disorders of the
immune system require treatment. Standard treatment involves anticancer
drugs such as fludarabine, chlorambucil, and corticosteroids (reviewed
in Wendtner et al4). However, despite high-dose
chemotherapy with stem cell support and the introduction of new
chemotherapeutic agents, treatment is rarely curative, and most
patients will eventually die from complications of CLL.4,5
Thus, new therapeutic options are needed.
Targeted therapies with monoclonal antibodies or immunotoxins have been
introduced into the clinic in recent years. Monoclonal antibodies to
B-cell antigens can induce clinical remissions in non-Hodgkin
lymphomas, including B-CLL.6 Immunotoxins contain a
protein toxin, which causes cell death upon internalization into cells,
in addition to a targeting monoclonal antibody or a fragment thereof,
or a ligand for cellular receptors (for review see Pastan and
FitzGerald7 and Frankel et al8).
A recombinant immunotoxin, anti-Tac(Fv)-PE38 (LMB-2), which is
directed against the LMB-2 is a single-chain immunotoxin composed of the variable heavy
domain region of a monoclonal antibody, anti-Tac,11 fused via a 15-amino acid linker to the variable light domain, which in turn
is fused to PE38, a truncated form of Pseudomonas
exotoxin.12,13 Truncated toxins such as PE38 are
internalized only after binding to target cell
protein.14,15 Pseudomonas exotoxin and
immunotoxins containing PE38 cause cell death by inhibition of protein
synthesis due to inactivation of elongation factor 2.16,17
The mode of cytotoxicity includes binding of the immunotoxin to CD25,
internalization and processing of the toxin within its translocation
domain,18 binding of the 35-kd carboxy-terminus of the
toxin intracellularly to the KDEL receptor that carries it to the
endoplasmatic reticulum,19 translocation of the toxin into
the cytosol,20,21 and catalytic adenosine diphosphate
(ADP)-ribosylation of elongation factor 2.16,17 As a
result of inhibition of protein synthesis, apoptosis and cell death are
induced.22 In addition, LMB-2 can kill cells without
induction of caspase-dependent apoptosis.22
In preclinical studies performed in murine xenograft models, LMB-2 has
shown high cytotoxic activity against tumor cells that express
CD25.13 Furthermore, freshly isolated cells from adult human T-cell leukemia are very sensitive to this immunotoxin in tissue
culture.23,24 HCL is particularly sensitive to LMB-2, mainly because these cells express very high levels of the respective antigen, CD25.25 However, LMB-2 is not as toxic to CLL
samples.26 The numbers of CD25 sites per cell are
considerably lower in B-CLL compared with HCL.25
Expression of surface antigens on B cells is not invariant, but is
modulated upon activation during the process of immune response.
Bacterial DNA and mimicking synthetic ODN sequences possess
immunostimulatory properties as recently recognized (for review see
Wagner27 and Krieg and Wagner28). Unmethylated CpG dinucleotide motifs are present at the expected frequency (1 in 16)
in bacterial DNA, whereas CpG dinucleotides are suppressed and
methylated in mammalian DNA.29 Thereby, cells of the
immune system are enabled to distinguish bacterial DNA from self-DNA. This leads to the initiation of inflammatory responses. Bacterial DNA
and ODNs containing an unmethylated CpG motif activate
monocytes,30 dendritic cells,31 and B
cells.32,33 CpG-ODNs have been demonstrated to be
effective adjuvants in tumor antigen immunization.34,35 Furthermore, they can enhance the antitumor response to monoclonal antibody therapy of lymphoma.36 CpG-ODNs are currently
being evaluated in clinical phase I/II studies in this
setting.37
We have recently reported that B-CLL cells are also stimulated by
treatment with an ODN containing a CpG-dinucleotide.38 This CpG-ODN, DSP30, leads to proliferation of B-CLL cells, furthermore to cytokine production and up-regulation of cell surface molecules including CD40, CD54, CD80, CD86, and major histocompatibility complex
(MHC) class I molecules.39 Up-regulation of functional interleukin-2 receptors increases the immunogenicity of leukemic cells
in the presence of interleukin-2.39
In the present work, we investigate whether up-regulation of CD25
increases the antileukemic efficacy of the immunotoxin LMB-2 in B-CLL.
We find that exposure to a CpG-ODN renders primary B-CLL cells from
peripheral blood of patients better targets for treatment with the
immunotoxin. Thereby, the majority of unresponsive B-CLL cell samples
are sensitized to LMB-2 at concentrations that are achievable in
patients. In contrast, the cytotoxicity of LMB-2 toward normal B and T
lymphocytes is only slightly increased upon concomitant treatment with
the CpG-ODN.
Patients and immunomagnetic separation of B-CLL cell
samples
Enrichment of B-CLL cells by density gradient centrifugation over a
Ficoll-Hypaque layer and immunomagnetic depletion of T lymphocytes and
monocytes has been described.39 The content of
CD19+ cells was more than 98% pure in the immunoseparated
cell samples. Similarly, tonsillar B cells were enriched as described
for B-CLL cells, resulting in a purity of more than 95%
CD19+ cells. T cells were purified from peripheral blood by
depletion of B lymphocytes and monocytes as described.39
Cells were immediately used for further experiments or resuspended in
fetal calf serum (FCS) with 10% dimethyl sulfoxide (DMSO) and stored
in liquid nitrogen until use. Control experiments demonstrated similar
results when frozen or fresh cells from the same sample were used.
Reagents, antibodies, immunotoxins, and cell lines
Fluorescein isothiocyanate (FITC)-conjugated monoclonal
antibodies to CD3, CD19, CD22, and CD25, as well as the appropriate isotype control were purchased from Beckman Coulter-Immunotech (Krefeld, Germany). The immunotoxins LMB-2 (also designated
anti-Tac(Fv)-PE38, directed to the CD25 antigen), BL22
(RFB4(dsFv)-PE38, specific for CD22), and LMB-9 (B3(dsFv)-PE38,
specific for a LewisY antigen) were developed and produced
as described.19,42-44 The immunotoxins were diluted in
phosphate buffered saline (PBS) to stock concentrations of 480 µg/mL
(LMB-2), 960 µg/mL (LMB-9), and 763 µg/mL (BL22), and stored as
aliquots at Culture conditions and proliferation assay Purified normal or leukemic B cells were cultured in RPMI 1640 medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (Biochrom), 50 IU/mL penicillin/streptomycin, 1 mM sodium pyruvate, L-glutamine at 2 mM, 20 µg/mL L-asparagine, 0.05 mM 2-mercaptoethanol, 10 mM HEPES, and MEM nonessential amino acids 0.7x (Biochrom). All tissue culture experiments were performed at 37°C and 5% CO2 in a fully humidified atmosphere in 96-well plates at 3 × 105 cells in a total volume of 100 µL for 5 days. At the end of the culture period, an (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay was performed: 10 µL of a combined MTS/phenazine methosulfate (PMS) solution (Promega, Mannheim, Germany) was added, and the optical density at 490 nm (OD490) was determined using an enzyme-linked immunosorbent assay (ELISA) reader. Mean values were calculated from triplicate cultures. To correct for background activity, cells were cultured in the presence of cycloheximide (Sigma) at 10 µg/mL. Results are depicted as the percentage of OD in comparison with cells cultured in the absence of immunotoxin. This was calculated using the following equation: (OD490 of cells without immunotoxin OD490 of cells cultured with
cycloheximide)/(OD490 of cells cultured in the presence of
immunotoxin/ OD490 of cells cultured with
cycloheximide). Data from individual experiments are presented as mean
plus or minus SEM. We confirmed our results with the trypan blue
exclusion method in 2 independent samples.
Immunophenotyping Cells were washed in PBS containing 2% FCS and incubated with saturating amounts of fluorochrome-conjugated monoclonal antibody or an equal amount of a nonbinding, isotype-identical control antibody. Fluorochromes were either FITC or phycoerythrin (PE). After 30 minutes at 4°C, cells were washed with PBS/2% FCS and analyzed via flow cytometry using a Coulter Epics XL cytofluorometer, acquiring 10 000 events. Data were analyzed using WinMDI 2.8 FACS software. The relative expression of surface antigen is described as the mean fluorescence intensity ratio. This value equals the mean fluorescence intensity of cells stained with a fluorochrome-conjugated antigen-specific antibody, divided by the mean fluorescence intensity of cells stained with a fluorochrome-conjugated isotype control antibody.
Up-regulation of CD25 expression by immunostimulatory ODNs B-CLL cells in peripheral blood of patients expressed low amounts of the CD25 antigen (Figure 1A). Upon a 2-day exposure to ODN DSP30, which contained a CpG motif, CD25 expression was up-regulated in a dose-dependent fashion. At 0.1 µM of DSP30, anti-CD25 fluorescence intensity was increased more than 10-fold with a further increase at 1 µM. In contrast, pZ27, a control ODN with no CpG motif, failed to increase CD25 expression at 0.1 µM and displayed only minor effects at 1 µM. C27, a phosphorothioate ODN, was used as a control to exclude that a nonspecific immunostimulatory effect of the backbone was responsible for the observed effect. No up-regulation of CD25 was observed even at 1 µM (Figure 1A). CD25 up-regulation could be detected after 8 hours of culture with DSP30, but longer incubation periods (48 hours to 72 hours) are needed for maximal up-regulation (Figure 1B).
An overview of all patient samples tested is displayed in Figure 1C. CD25 expression was markedly induced in 12 of 13 (92%) of the samples. In only one sample was no CD25 up-regulation observed. The relative increase, however, varied from one patient to another. Two samples (patient no. 8 and patient no. 12) could not be evaluated because the CLL cells died in the presence of DSP30 (cell viability reduced to 13% and 26% of control, respectively, in the presence of DSP30 without immunotoxin). Sensitization of B-CLL cells to LMB-2 immunotoxin by DSP30 B-CLL cells were incubated for 5 days with LMB-2 at 1 µg/mL and various concentrations of DSP30, pZ27, or C27. Thereafter, cell viability was assessed colorimetrically with an MTS assay. As shown in Figure 2A, the cytotoxicity of LMB-2 was increased upon addition of DSP30. Sensitization by DSP30 was dose dependent with a maximum effect at 1 µM. It should be noted that DSP30 exerted no cytotoxic effect in B-CLL cells from these patients if LMB-2 was not added. DSP30 caused a moderate increase of cell viability in the absence of LMB-2 (average: 40% increase in OD490 in 15 patient samples). Thus, the interaction of DSP30 and LMB-2 appears to be synergistic. Different from DSP30, the control ODNs pZ27 and C27 failed to modulate the toxicity of LMB-2 (Figure 2A). Sensitization of B-CLL cells to LMB-2 in the presence of DSP30 was first detectable after 72 hours, but maximal effects were observed after 96 to 120 hours (Figure 2B).
Next, we investigated inhibition of B-CLL growth by DSP30 and LMB-2 in
a series of 13 patients. (Samples from patient no. 8 and
patient no. 12 had to be excluded because DSP30 was cytotoxic to these
cells.) In the presence of DSP30 at 1 µM, B-CLL cells from 12 patients were growth inhibited by LMB-2 after a 5-day incubation.
OD490 was reduced from 0.37 ± 0.06 to 0.13 ± 0.05 in
13 samples after incubation with DSP30 and LMB-2 at 1 µg/mL. The
concentrations, at which LMB-2 inhibited cell growth by 50% (IC50), were below 1 µg/mL (Figure
3). Moreover, in 9 of 13 samples, the
IC50 was 100 ng/mL or below.
B-CLL cells from patient no. 13 did not respond to LMB-2 in combination with DSP30, as the ODN failed to up-regulate CD25 expression in this leukemia (Figure 1C). Although increased cytotoxicity of LMB-2 was only observed in samples in which CD25 was up-regulated, the amounts of CD25 expression as assessed by flow cytometry were not significantly correlated with the respective IC50 values. For instance, B-CLL cells from patient no. 15 were sensitized most efficiently (Figure 3) although CD25 expression levels were higher in other samples (eg, in patient no. 10 and patient no. 11) (Figure 1B). As a specificity control, B-CLL cells from each patient were incubated with DSP30 in combination with LMB-9, an immunotoxin targeting a LewisY carbohydrate antigen, which is present on adenocarcinoma cells but not on hematopoietic tissues.40,42 No activity of LMB-9 was observed in any sample (Figure 3). The antileukemic efficacy of LMB-2 was detectable only in cells treated
with DSP30. In contrast, if B-CLL cells were incubated under otherwise
identical conditions with LMB-2 in the absence of DSP30, no
antileukemic activity was detectable (Figure
4) with an OD490 remaining
unchanged (0.27 ± 0.03 versus 0.28 ± 0.03). Twelve B-CLL samples
were evaluable for this analysis since cells from patients no. 7, no.
11, and no. 14 died spontaneously in tissue culture unless the ODN was
added.
The effects of DSP30 were related to increased expression of the
target antigen, CD25. To exclude the possibility of a nonspecific interaction of DSP30 with a toxin, we performed a control experiment with an immunotoxin to a different surface antigen on B-CLL cells. CD22, the target of the immunotoxin BL22, was only slightly
up-regulated upon treatment of B-CLL cells with DSP30 (Figure
5A). Dose-response experiments revealed
similar sensitivities to BL22 in the presence or in the absence of
DSP30 (Figure 5B). In conclusion, the CpG-ODN sensitizes B-CLL cells to
the cytotoxicity of immunotoxin LMB-2 specifically by up-regulation of
the respective target antigen on the cell surface.
Toxicity of LMB-2 to normal lymphocytes Sensitization of B-CLL cells to an immunotoxin could be a potentially harmful treatment approach if the toxicity toward normal lymphocytes were increased accordingly. We therefore analyzed the effects of DSP30 and LMB-2 in normal T lymphocytes from peripheral blood, and B cells from tonsils of patients undergoing tonsillectomy for nonmalignant disease. Figure 6A shows that incubation with DSP30 increased CD25 expression in purified normal B lymphocytes only moderately compared with B-CLL cells. No increase was observed in normal T cells (Figure 6B). These results were confirmed with experiments in which unseparated peripheral blood mononuclear cells (PBMCs) from patients with B-CLL were analyzed. These samples contained T cells (Figure 6C). CD25 was up-regulated by the ODN only in CD19+ B cells, but not in CD3+ T lymphocytes.
In unstimulated B and T lymphocytes, no specific cytotoxicity of LMB-2
was detected above the level of LMB-9 toxicity (Figure 7). Furthermore, LMB-2 was relatively
untoxic to DSP30-treated normal lymphocytes of both lineages (Figure
7). In summary, both up-regulation of CD25 expression and sensitization
to the toxicity of LMB-2 are more pronounced in B-CLL cells than in
normal lymphocytes.
We have shown that B-CLL cells resistant to a recombinant immunotoxin targeting CD25 are efficiently sensitized upon treatment with immunostimulatory phosphorothioate ODN. To our knowledge, this is the first report that modulation of surface antigen expression on malignant cells by CpG-ODN leads to sensitization to an immunotoxin or an antibody. In our study, the immunotoxin LMB-2 exerted no cytotoxicity toward B-CLL cells unless CpG-ODNs were present. Addition of the CpG-ODN decreased the IC50 of LMB-2 to concentrations that are in the range of plasma levels in patients.10 Up-regulation of CD25 by CpG-ODN was observed in all but one of the B-CLL samples. Sensitization to the immunotoxin LMB-2 was specifically due to the up-regulation of the CD25 target because BL22, another immunotoxin whose target antigen was modulated to a much lesser extent, displayed similar cytotoxicity with or without CpG-ODN. In addition, the truncated Pseudomonas exotoxin domain was not involved in an interaction with the immunostimulatory ODN because the cells were not sensitized to immunotoxin LMB-9, which does not recognize B-CLL cells. LMB-2 is very cytotoxic to various cells expressing CD25, with fewer than 1000 molecules per cell being sufficient for complete responses in an in vivo model.45 Thus, the presence of adequate numbers of binding sites is a prerequisite for the efficacy of an immunotoxin. Most HCL and T-cell leukemia cells express higher numbers of CD25 molecules than B-CLL cells.25 Nonetheless, it is not obvious that increased numbers of CD25 molecules after CpG-ODN treatment are sufficient for sensitization to LMB-2. B-CLL cells tend to be generally less sensitive to LMB-2 than HCL or T-cell leukemia cells even if comparable numbers of binding sites are present.25 It has been suggested that HCL cells are more efficient than B-CLL cells in internalizing and intracellularly transporting the immunotoxin.25 Multiple steps are required to ensure that the toxin is delivered in its active form to bind to elongation factor 2.16-22 Results presented here suggest that, following stimulation with CpG-ODN, the numbers of CD25 target molecules on the surface of B-CLL cells are high enough to overcome this limitation. In our study, all B-CLL samples failed to respond to LMB-2 in the absence of ODN. In contrast, Kreitman and coworkers reported that a similar immunotoxin, anti-Tac(Fv)-PE40KDEL, inhibited protein synthesis in 50% of CLL samples.26 Besides differences among individual patients, several reasons may account for this discrepancy. First, the incubation periods were different, 60 to 62 hours versus 5 days. We used longer incubation periods to allow for up-regulation of the target structure. Moreover, the sensitivity of B-CLL cytotoxicity assays depends on cell densities. In a study by Robbins et al in which extremely high densities were used, better responses were observed compared with our study as well as a previous study by Kreitman and coworkers.25,26 Second, the MTS assay used in the present study determines cell viability, whereas Kreitman and coworkers analyzed protein synthesis by incorporation of radiolabeled leucine. Since inhibition of protein synthesis is the cellular mechanism interrupted by PE38, it is possible that assessment of cell viability by an MTS assay underestimates the toxicity of LMB-2 in comparison with the leucin incorporation assay. Third, the toxin containing a KDEL sequence is more toxic to B-CLL cells than LMB-2.25 Whereas the native carboxy-terminus of LMB-2 consists of the amino acids REDLK, the KDEL sequence binds to the intracellular KDEL receptor with higher affinity, resulting in more efficient transport to the endoplasmatic reticulum and higher cytotoxicity.19,46 LMB-2 has been introduced into the clinic because preclinical studies demonstrated lower systemic toxicity in primates than the respective, KDEL-containing toxin. The mode by which LMB-2 exerts its cytotoxicity to B-CLL cells is not fully understood. Preliminary investigations have revealed that caspase-3-mediated apoptosis is involved in some, but not all patients (data not shown). This is in accord with observations in permanent cell lines. Whereas most cells die following induction of apoptosis, HUT-102 leukemic cells from a patient with mycosis fungoides are being killed without activation of caspases.22 The mechanism by which apoptosis-resistant CLL cells are killed requires further study. In addition, the schedule of exposure to CpG-ODN and immunotoxin need not necessarily be optimal. We have incubated B-CLL cells simultaneously with LMB-2 and CpG-ODN. This schedule was chosen for practical reasons. Because of the limited stability of LMB-2, it is conceivable that a sequential application where the toxin is added after prior stimulation of cells with CpG-ODN may be more efficient. Further studies should determine the time course of CD25 induction by CpG-ODN, and optimize the conditions for antileukemic treatment. This is pertinent before a combination therapy of LMB-2 and CpG-ODN can be introduced into the clinic. CpG-ODNs have been evaluated in murine and primate animal models and are currently being studied in early clinical trials (reviewed in Weiner37). CpG-ODNs were generally well tolerated. However, repeated application of large doses can cause a wasting syndrome in rodents due to cytokine production and proliferation of natural killer (NK) cells and B lymphocytes.37,47 We have demonstrated that stimulation with DSP30 does not sensitize normal B cells and T cells to treatment with an immunotoxin (Figure 6, Figure 7), but further investigations (eg, in animal models) are needed before treatment with both substances can be started in clinical trials. The CpG motif is important for maximal stimulation of human B cells but phosphorothioate ODNs, which have been most stimulatory in mice, have demonstrated only weak activity in human immune cells.48,49 Other motifs such as TCG repeats (which are present at the 5' end of DSP30) might be important as well.33,48 Although nonspecific effects of the phosphorothioate backbone have been described,50 a highly active phosphodiester CpG-ODN has been described recently.48 The effects observed in our study are not primarily due to the phosphorothioate backbone because no sensitization was observed in the presence of the phosphorothioate ODN C27. Although stimulation of leukemic growth by CpG-ODN would be a major concern to clinical application of these compounds, the proliferative capacity of CpG-ODN-treated B-CLL cells was weaker than that of normal lymphocytes.38 In contrast, the CD25 up-regulation was much stronger in B-CLL cells than in normal peripheral blood B cells or tonsillar B cells (Figure 6 and Decker et al39). Therefore, normal B cells might fail to reach a threshold expression of CD25 for effective cell kill by the immunotoxin. Our current study confirms that sensitization to the immunotoxin outweighs the growth-stimulatory effects in B-CLL cells. Furthermore, the increased sensitivity of B-CLL cells compared with normal lymphocytes to a combination of CpG-ODN and the immunotoxin allows selective intervention. The increased immunogenicity of B-CLL cells treated with
CpG-ODN38,39 may result in additional antitumor effects.
CpG-ODNs have been used as adjuvants in tumor
immunization.34,35,51 In mice they induce rejection of
neuroblastoma xenografts50 and inhibit the growth of B16
melanoma.37 The antitumor activity is most likely related
to activation of NK cells,37,52,53 and induction of the
production of cytokines with anticancer activity such as
interleukin-12, tumor necrosis factor- Further studies should determine whether the immunostimulatory effect of CpG-ODN is maintained upon combination with the immunotoxin. Death of B-CLL cells after treatment with a combination of CpG-ODN and immunotoxin may even cause an increased immune response due to antigen presentation by apoptotic cells. It has been shown in an animal model that CpG-ODNs increase the efficacy of monoclonal antibodies to murine 38C13 lymphomas.36 In that study, the cytolytic activity of NK cells was enhanced by CpG-ODNs. A single injection with CpG-ODN was as effective as multiple administrations of interleukin-2 in inducing antitumor immunity if combined with a monoclonal antibody. Thus, antibody-dependent cellular toxicity is thought to play a major role in the immunostimulatory activity of CpG-ODNs. Whether or not the phenotype of lymphoma cells was changed was not reported in this study. Our investigation shows that the modulation of antigen expression on malignant cells by CpG-ODNs can significantly contribute to the antitumor activity of an immunotoxin. Up-regulation of target molecules for potential antibody therapy by CpG-ODN is not confined to B-CLL but has been recently reported in other non-Hodgkin lymphoma entities.56 Therefore, it appears possible that additional applications for this new treatment approach can be identified.
We wish to thank H. Wagner for helpful discussions and Maria Gallo for critically reading the manuscript.
Submitted March 9, 2001; accepted September 27, 2001.
Supported by a research grant from the Technical University of Munich, Germany, (KKF H30-97), and by a grant from the Deutsche Forschungsgemeinschaft (De 771/1-1).
One of the authors (I.P.) has declared a financial interest in a company whose product was studied in the present work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Thomas Decker, 3rd Department of Medicine, Technical University of Munich, Ismaninger Str 15, 81675 Munich, Germany; e-mail: t.decker{at}lrz.tum.de.
1.
Rozman C, Montserrat E.
Current concepts: chronic lymphocytic leukemia.
N Engl J Med.
1995;333:1052-1057
2.
O`Brien S, Del Giglio A, Keating M.
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Blood.
1995;85:307-318 3. Reed CJ. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol. 2000;37:9-16[Medline] [Order article via Infotrieve].
4.
Wendtner CM, Schmitt B, Wilhelm M, et al.
Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk adapted therapy.
Ann Oncol.
1999;10:505-509 5. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcomittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). Brit J Haematol. 2000;108:595-601[CrossRef][Medline] [Order article via Infotrieve].
6.
Hainsworth JD, Burris HA, Morrissey LH, et al.
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.
Blood.
2000;95:3052-3056
7.
Pastan I, FitzGerald D.
Recombinant toxins for cancer treatment.
Science.
1991;254:1173-1177
8.
Frankel AE, Kreitman RJ, Sauasville EA.
Targeted toxins.
Clin Cancer Res.
2000;6:326-334
9.
Kreitman RA, Wilson WH, Robbins D, et al.
Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Blood.
1999;94:3340-3348
10.
Kreitman RA, Wilson WH, White JD, et al.
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
J Clin Oncol.
2000;18:1622-1636 11. Uchiyama TA, Broder S, Waldmann TA. A monclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126:1393-1397[Medline] [Order article via Infotrieve]. 12. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-397[CrossRef][Medline] [Order article via Infotrieve].
13.
Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I.
Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Blood.
1994;83:426-434 14. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987;48:129-136[CrossRef][Medline] [Order article via Infotrieve].
15.
Kondo T, FitzGerald D, Chaudhary VK, Adhya S, Pastan I.
Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.
J Biol Chem.
1988;263:9470-9475
16.
Mozola MA, Wilson RB, Jordan EM, Draper RK, Clowes RC.
Cloning and expression of a gene segment encoding the enzymatic moiety of Pseudomonas aeruginosa exotoxin A.
J Bacteriol.
1984;159:683-687
17.
Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I.
Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin.
J Biol Chem.
1989;264:14256-14261
18.
Ogata M, Fryling CM, Pastan I, FitzGerald DJ.
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.
J Biol Chem.
1992;267:25396-25401 19. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J. 1995;307:29-37.
20.
Jinno Y, Ogata M, Chaudhary VK, et al.
Domain II mutants of Pseudomonas exotoxin deficient in translocation.
J Biol Chem.
1989;264:15953-15959
21.
Theuer CP, Buchner J, FitzGerald D, Pastan I.
The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion.
Proc Natl Acad Sci U S A.
1993;90:7774-7778 22. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer. 2000;87:86-94[CrossRef][Medline] [Order article via Infotrieve].
23.
Kreitman RJ, Chaudhary VK, Waldmann T, Willingham MC, FitzGerald DJ, Pastan I.
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Proc Natl Acad Sci U S A.
1990;87:8291-8295 24. Kreitman RJ, Chaudhary VK, Waldmann T, et al. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas exotoxin or diphteria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia. 1993;7:553-562[Medline] [Order article via Infotrieve].
25.
Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ.
Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Clin Cancer Res.
2000;6:693-700 26. Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood. 1992;80:2334-2352. 27. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368[Medline] [Order article via Infotrieve]. 28. Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progress from bacteria to bacterial DNA. Immunol Today. 2000;21:521-526[CrossRef][Medline] [Order article via Infotrieve]. 29. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity. 1996;5:303-310[CrossRef][Medline] [Order article via Infotrieve]. 30. Bauer M, Heeg K, Wagner H, Lipford GB. DNA activates human immune cells through a CpG sequence dependent manner. Immunology. 1999;97:699-705[CrossRef][Medline] [Order article via Infotrieve].
31.
Hartmann G, Weiner G, Krieg AM.
CpG DNA as a signal for growth, activation and maturation of human dendritic cells.
Proc Natl Acad Sci U S A.
1999;96:9305-9310 32. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549[CrossRef][Medline] [Order article via Infotrieve]. 33. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky P. Activation of human B cells by phosphorothioate oligonucleotides. J Clin Invest. 1996;98:1119-1129[Medline] [Order article via Infotrieve].
34.
Davila E, Celis E.
Repeated administration of cytosine-phosphorothiolated gunanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
J Imunol.
2000;165:539-547
35.
Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H.
CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
J Immunol.
2000;164:2372-2378
36.
Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ.
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Blood.
1997;89:2994-2998
37.
Weiner GJ.
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
J Leukocyte Biol.
2000;68:455-463
38.
Decker T, Schneller F, Sparwasser T, et al.
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients.
Blood.
2000;95:999-1006 |
Top
Abstract
Introduction
-chain of the interleukin-2 receptor (also
referred to as Tac or CD25 antigen), has been investigated in patients
with malignant lymphomas.
indicates LMB-2; 
,
LMB-9.
.